Natl Toxicol Program Tech Rep Ser. 2006 Feb(532):1-248.
Bromodichloromethane is a by-product of the chlorination of drinking water. It is formed by the halogen substitution and oxidation reactions of chlorine with naturally occurring organic matter (e.g., humic or fulvic acids) in water containing bromide. Bromodichloromethane has been shown to be carcinogenic at multiple sites in rats (large intestine and kidney) and in mice (liver and kidney) after administration by gavage in corn oil. To further characterize its dose-response relationships for evaluations of human risk, bromodichloromethane was nominated to the NTP by the United States Environmental Protection Agency for toxicity and carcinogenicity studies in rats and mice by drinking water exposure. Male F344/N rats and female B6C3F1 mice were exposed to bromodichloromethane (greater than 98% pure) in drinking water for 3 weeks or 2 years. Genetic toxicology studies were conducted in Salmonella typhimurium, L5178Y mouse lymphoma cells, cultured Chinese hamster ovary cells, mouse bone marrow cells, and mouse peripheral blood erythrocytes. 3-WEEK STUDY IN RATS: Groups of 10 male F344/N rats were exposed to target concentrations of 0, 43.7, 87.5, 175, 350, or 700 mg/L bromodichloromethane (equivalent to average daily doses of approximately 0, 6, 12, 20, 38, or 71 mg bromodichloromethane/kg body weight) in drinking water for 3 weeks. All rats survived to the end of the study. The mean body weight gains of 350 and 700 mg/L rats were significantly less than that of the controls. Concentration-related decreases in water consumption were evident during the first week on study. Relative kidney weights of rats in the 175, 350, and 700 mg/L groups were significantly greater than that of the controls. There were no significant chemical-related histopathological changes. 3-WEEK STUDY IN MICE: Groups of 10 female B6C3F1 mice were exposed to target concentrations of 0, 43.7, 87.5, 175, 350, or 700 mg/L bromodichloromethane (equivalent to average daily doses of approximately 0, 6, 10, 16, 29 or 51 mg/kg) in drinking water for 3 weeks. All mice survived to the end of the study. Final mean body weights of the 175, 350, and 700 mg/L mice and mean body weight gains of 350 and 700 mg/L mice were significantly less than those of the controls. These decreases were attributed to decreased water consumption. There were significant concentration-related decreases in water consumption by groups exposed to 87.5 mg/L or greater throughout the study; these decreases were attributed to poor palatability of the dosed water. Relative liver, kidney, and thymus weights of mice in the 350 and 700 mg/L groups were significantly greater than those of the controls. Absolute lung weights of mice in the 350 and 750 mg/L groups were significantly less than that of the controls. There were no significant chemical-related histopathological changes. 2-YEAR STUDY IN RATS: Groups of 50 male F344/N rats were exposed to target concentrations of 0, 175, 350, or 700 mg/L bromodichloromethane (equivalent to average daily doses of approximately 0, 6, 12, or 25 mg/kg) in drinking water for 2 years. Survival of exposed groups was similar to that of the controls. Mean body weights of all exposed groups were generally similar to those of the controls throughout the study. Water consumption by exposed rats was less than that by the controls throughout the study; the decreases were attributed to poor palatability of the dosed water. There were no increased incidences of neoplasms that were attributed to bromodichloromethane. The incidences of chronic inflammation in the liver of the 350 and 700 mg/L groups were significantly greater than that in the controls; however, the biological significance of these increases is uncertain. 2-YEAR STUDY IN MICE: Groups of 50 female B6C3F1 mice were exposed to target concentrations of 0, 175, 350, 700 mg/L bromodichloromethane (equivalent to average daily doses of approximately 9, 18, or 36 mg/kg) in drinking water for 2 years. Survival of exposed groups was similar to that of the controls. Mean body weights of all exposed groups were generally less than those of the controls from week 4 through the end of the study. Water consumption by exposed mice was less than that by the controls throughout the study; the decreases were attributed to poor palatability of the dosed water. The incidences of hepatocellular adenoma or carcinoma (combined) occurred with a negative trend, and the incidence in the 700 mg/L group was significantly decreased relative to the control group. The incidence of hemangiosarcoma in all organs was significantly decreased in the 350 mg/L group.
The results of in vitro mutagenicity tests with bromodichloromethane were mixed. Bromodichloromethane did not induce mutations in any of several tester strains of Salmonella typhimurium, with or without exogenous metabolic activation (S9 liver enzymes). In contrast to the negative results in Salmonella, tests for mutation induction in mouse lymphoma L5178Y/tk(+/-)cells were positive in the presence of induced rat liver S9; no mutagenic activity occurred in tests conducted without S9. In cytogenetic tests with cultured Chinese hamster ovary cells, bromodichloromethane induced a small increase in sister chromatid exchanges (SCEs) in one of four trials conducted in the presence of induced rat liver S9 enzymes; no significant increase in SCEs occurred without S9, and no induction of chromosomal aberrations occurred in bromodichloromethane-treated Chinese hamster ovary cells with or without S9. Results of in vivo tests for chromosomal damage were negative. No increases in the frequency of micronucleated erythrocytes were seen in bone marrow of male B6C3F1 mice administered bromodichloromethane by intraperitoneal injection for 3 days. In addition, no induction of micronuclei was observed in circulating erythrocytes of female B6C3F1 mice administered up to 700 mg/L bromodichloromethane in drinking water for 3 weeks.
Under the conditions of this 2-year drinking water study, there was no evidence of carcinogenic activity of bromodichloromethane in male F344/N rats exposed to target concentrations of 175, 350, or 700 mg/L. There was no evidence of carcinogenic activity of bromodichloromethane in female B6C3F1 mice exposed to target concentrations of 175, 350, or 700 mg/L.
溴二氯甲烷是饮用水氯化过程中的副产物。它由含溴水中氯与天然有机物(如腐殖酸或富里酸)的卤代和氧化反应形成。经玉米油灌胃给药后,溴二氯甲烷已被证明可在大鼠(大肠和肾脏)和小鼠(肝脏和肾脏)的多个部位致癌。为进一步确定其剂量反应关系以评估人类风险,美国环境保护局将溴二氯甲烷提交给美国国家毒理学计划,用于通过饮水暴露对大鼠和小鼠进行毒性和致癌性研究。雄性F344/N大鼠和雌性B6C3F1小鼠饮用含溴二氯甲烷(纯度大于98%)的水3周或2年。在鼠伤寒沙门氏菌、L5178Y小鼠淋巴瘤细胞、培养的中国仓鼠卵巢细胞、小鼠骨髓细胞和小鼠外周血红细胞中进行了遗传毒理学研究。
大鼠3周研究:将10只雄性F344/N大鼠分为几组,饮用含目标浓度0、43.7、87.5、175、350或700 mg/L溴二氯甲烷的水(相当于平均每日剂量约0、6、12、20、38或71 mg溴二氯甲烷/千克体重)3周。所有大鼠均存活至研究结束。350和700 mg/L组大鼠的平均体重增加显著低于对照组。在研究的第一周,饮水量出现与浓度相关的下降。175、350和700 mg/L组大鼠的相对肾脏重量显著高于对照组。未观察到与化学物质相关的显著组织病理学变化。
小鼠3周研究:将10只雌性B6C3F1小鼠分为几组,饮用含目标浓度0、43.7、87.5、175、350或700 mg/L溴二氯甲烷的水(相当于平均每日剂量约0、6、10、16、29或51 mg/kg)3周。所有小鼠均存活至研究结束。175、350和700 mg/L组小鼠的最终平均体重以及350和700 mg/L组小鼠的平均体重增加显著低于对照组。这些下降归因于饮水量减少。在整个研究过程中,暴露于87.5 mg/L或更高浓度组的小鼠饮水量出现与浓度相关的显著下降;这些下降归因于给药水的适口性差。350和700 mg/L组小鼠的肝脏、肾脏和胸腺相对重量显著高于对照组。350和750 mg/L组小鼠的绝对肺重量显著低于对照组。未观察到与化学物质相关的显著组织病理学变化。
大鼠2年研究:将50只雄性F344/N大鼠分为几组,饮用含目标浓度0、175、350或700 mg/L溴二氯甲烷的水(相当于平均每日剂量约0、6、12或25 mg/kg)2年。暴露组的存活率与对照组相似。在整个研究过程中,所有暴露组的平均体重通常与对照组相似。暴露大鼠的饮水量在整个研究过程中均低于对照组;下降归因于给药水的适口性差。未观察到归因于溴二氯甲烷的肿瘤发生率增加。350和700 mg/L组大鼠肝脏慢性炎症的发生率显著高于对照组;然而,这些增加的生物学意义尚不确定。
小鼠2年研究:将50只雌性B6C3F1小鼠分为几组,饮用含目标浓度0、175、350、700 mg/L溴二氯甲烷的水(相当于平均每日剂量约9、18或36 mg/kg)2年。暴露组的存活率与对照组相似。从第4周直至研究结束,所有暴露组的平均体重通常低于对照组。暴露小鼠的饮水量在整个研究过程中均低于对照组;下降归因于给药水的适口性差。肝细胞腺瘤或癌(合并)的发生率呈负趋势,700 mg/L组的发生率相对于对照组显著降低。350 mg/L组所有器官血管肉瘤的发生率显著降低。
溴二氯甲烷的体外致突变性试验结果不一。溴二氯甲烷在有或无外源性代谢激活(S9肝酶)的情况下,均未在几种鼠伤寒沙门氏菌测试菌株中诱导突变。与沙门氏菌的阴性结果相反,在诱导大鼠肝脏S9存在的情况下,小鼠淋巴瘤L5178Y/tk(+/-)细胞的突变诱导试验呈阳性;在无S9的试验中未发生诱变活性。在用培养的中国仓鼠卵巢细胞进行的细胞遗传学试验中,在存在诱导大鼠肝脏S9酶的四项试验之一中,溴二氯甲烷诱导姐妹染色单体交换(SCE)略有增加;在无S9的情况下,SCE未显著增加,并且在有或无S9的溴二氯甲烷处理的中国仓鼠卵巢细胞中均未诱导染色体畸变。体内染色体损伤试验结果为阴性。通过腹腔注射给予溴二氯甲烷3天的雄性B6C3F1小鼠骨髓中,微核红细胞频率未见增加。此外,在饮用水中给予高达700 mg/L溴二氯甲烷3周的雌性B6C3F1小鼠的循环红细胞中未观察到微核诱导。
在这项为期2年的饮水研究条件下,未发现暴露于目标浓度175、350或700 mg/L的溴二氯甲烷对雄性F344/N大鼠有致癌活性的证据。未发现暴露于目标浓度175、350或700 mg/L的溴二氯甲烷对雌性B6C3F1小鼠有致癌活性的证据。